右美托咪定对老年骨科手术患者术后认知功能障碍的影响:随机对照试验研究方案
该单中心、前瞻性、双盲随机对照试验在河北省人民医院纳入96例接受全髋或全膝关节置换的老年患者,随机分为两组。试验组给予右美托咪定负荷剂量0.5 μg/kg持续10分钟,随后以0.5 μg/kg/h维持至手术结束前30分钟;对照组输注等量生理盐水。主要结局为术后认知功能障碍发生率,次要结局包括辅助性T细胞17与调节性T细胞平衡变化、基质金属蛋白酶9、S-100β、IL-17A和IL-10水平、围术期并发症、住院时长及术中失血量。
要点
- 试验在河北省人民医院开展,纳入96例全髋或全膝关节置换老年患者。
- 试验组右美托咪定负荷0.5 μg/kg持续10分钟,维持0.5 μg/kg/h至术毕前30分钟。
- 主要结局为术后认知功能障碍发生率,次要结局含Th17/Treg平衡及相关细胞因子。
核心结论
- 该试验结果将显示右美托咪定能否改善老年骨科患者术后认知功能障碍,其作用可能与辅助性T细胞17/调节性T细胞平衡有关。
研究设计与样本
- 单中心、前瞻性、双盲随机对照试验,在河北省人民医院开展,纳入96例接受全髋或全膝关节置换的老年患者,随机分为两组。
主要发现
- 试验组给予右美托咪定负荷剂量0.5 μg/kg持续10分钟,随后以0.5 μg/kg/h维持至手术结束前30分钟;对照组输注等量生理盐水。
- 主要结局为术后认知功能障碍发生率;次要结局包括辅助性T细胞17与调节性T细胞平衡变化、基质金属蛋白酶9、S-100β、IL-17A和IL-10水平、围术期并发症、住院时长及术中失血量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: This trial aims to assess whether dexmedetomidine can reduce the incidence of postoperative cognitive dysfunction in elderly orthopaedic patients and explore the specific mechanism. BACKGROUND: Postoperative cognitive dysfunction is a common complication after orthopaedic surgery that results in poor prognosis and increases the length of hospital stays and costs. Dexmedetomidine has been confirmed as a drug that can improve postoperative cognitive dysfunction in some studies. However, to date, the specific mechanism by which dexmedetomidine improves postoperative cognitive dysfunction is still elusive. METHODS/DESIGN: A single-centre, prospective, double-blinded, randomized controlled trial will be conducted at Hebei General Hospital. Ninety-six elderly patients who undergo total hip or knee replacement will be studied in this trial and randomly divided into two groups. Patients in the experimental group will receive a loading dose of 0.5 μg/kg dexmedetomidine for 10 min and then a maintenance dose of 0.5 μg/kg/h dexmedetomidine until 30 min before the end of the operation, and patients in the control group will be infused with an equal volume of normal saline. The incidence of postoperative cognitive dysfunction will be the primary outcome. Changes in the balance of T helper 17 cell and regulatory T cell; the levels of matrix metalloproteinase 9, S-100β, IL-17A, and IL-10; perioperative complications; hospitalization duration; and intraoperative blood loss will be the secondary outcomes. DISCUSSION: The consequences of this trial will show that dexmedetomidine can improve postoperative cognitive dysfunction in elderly orthopaedic patients, which may be related to the balance of T helper 17/regulatory T cells. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2200055802 . Registered on 20 January 2022.
引用
- Zhao W, Zhang H, Li J, et al. Effect of dexmedetomidine on postoperative cognitive dysfunction in elderly patients undergoing orthopaedic surgery: study protocol for a randomized controlled trial. Trials. 2023. PMID: 36703176. doi:10.1186/s13063-023-07110-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。